培菲康辅助治疗乙型肝炎后肝硬化的效果与安全性观察  

Efficacy and safety of Pefikan in adjuvant treatment of post-hepatitis B cirrhosis

作　　者：王超杰 姜海 Wang Chao-jie;Jiang Hai(Department of Infection,Hai’an People’s Hospital,Hai’an 226600,China)

机构地区：[1]海安市人民医院感染科,海安226600

出　　处：《中国药物应用与监测》2024年第6期743-746,共4页Chinese Journal of Drug Application and Monitoring

摘　　要：目的观察培菲康(双歧杆菌三联活菌胶囊)辅助治疗乙型肝炎后肝硬化的效果与安全性。方法纳入2020年1月至2023年12月海安市人民医院感染科收治的80例乙型肝炎后肝硬化患者,以随机数字表法分为恩替卡韦组及培菲康组各40例。恩替卡韦组患者口服恩替卡韦片治疗,培菲康组患者口服恩替卡韦片及培菲康治疗,比较两组的临床疗效、不良反应、治疗前后免疫指标(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))变化及肝功能指标[血清总胆红素(TBIL)、天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)]变化。结果培菲康组治疗总有效率为97.50%,高于恩替卡韦组(80.00%),差异有统计学意义(P<0.05);培菲康组治疗不良反应发生率为5.00%,恩替卡韦组为7.50%,差异无统计学意义(P>0.05);治疗后,培菲康组的CD4^(+)、CD4^(+)/CD8^(+)[分别为(49.65±3.85)%、(1.72±0.26)],均高于恩替卡韦组[分别为(44.85±4.26)%、(1.41±0.30)],培菲康组患者CD8^(+)为(28.67±3.36)%,低于恩替卡韦组(32.15±4.15)%,P<0.05;治疗后,培菲康组的TBIL、AST、ALT水平[分别为(39.64±5.99)μmol·L^(-1)、(42.39±3.53)U·L^(-1)、(39.65±4.94)U·L^(-1)],均低于恩替卡韦组患者[分别为(44.29±6.23)μmol·L^(-1)、(48.62±5.23)U·L^(-1)、(46.23±5.11)U·L^(-1)]差异有统计学意义(P<0.05)。结论培菲康辅助治疗乙型肝炎后肝硬化的效果良好,可较好地改善患者的免疫功能、肝功能,不良反应少,安全可靠。Objective To investigate the efficacy and safety of Pefican(Bifidobacterium triple viable capsule)in the adjuvant treatment of post-hepatitis B cirrhosis.Methods A total of 80 patients with post-hepatitis B cirrhosis admitted to Hai’an People’s Hospital from January 2020 to December 2023 were included and divided into the Entecavir group and Pefikan group by random number table method,with 40 in each group.The patients in the Entecavir group were treated with oral Entecavir tablets and those in the Pefican group with oral Entecavir tablets and pefican.The clinical efficacy,adverse reactions,changes of immune indexes(CD4^(+),CD8^(+),CD4^(+)/CD8^(+))and liver function indexes(serum total bilirubin(TBIL),aspartate aminotransferase(AST),alanine aminotransferase(ALT))before and after treatment were compared between the two groups.Results The total effective rate was significantly higher in the Pefican group than in the Entecavir group(97.50%vs 80.00%,P<0.05).The adverse reaction rate was 5.00%in the Pefican group and 7.50%in the Entecavir group,showing no statistically significant difference(P>0.05).After treatment,CD4^(+)and CD4^(+)/CD8^(+)were(49.65±3.85)%and(1.72±0.26),respectively in the Pefican group,higher than those of(44.85±4.26)%and(1.41±0.30)in the Entecavir group.The CD8^(+)was(28.67±3.36)%,lower than that of(32.15±4.15)%in the Entecavir group(P<0.05).The TBIL,AST and ALT levels in the Pefican group were(39.64±5.99)μmol·L^(-1),(42.39±3.53)U·L^(-1)and(39.65±4.94)U·L^(-1),respectively.They were lower than those of(44.29±6.23)μmol·L^(-1),(48.62±5.23)U·L^(-1),(46.23±5.11)U·L^(-1)in the Entecavir group(P<0.05).Conclusion The effect of Pefican in the adjuvant treatment of post-hepatitis B cirrhosis is good because it can improve the immune function and liver function.Meanwhile,its side effects are less and it is safe and reliable.

关 键 词：乙型肝炎后肝硬化 培菲康 肝功能 免疫功能 不良反应 

分 类 号：R512.62[医药卫生—内科学] R575.2[医药卫生—临床医学]